Ozempic, Wagovy, similar drugs could soon be covered
Anew University of Michigan studyshows that a strong majority of older Americans wanthealth insurance including Medicare to cover weight loss medications, as rising interest and evolving science change how people view obesity treatment.
Key points:
-
83% of older adultsbelieve insurance should cover weight loss drugs including Medicare.
-
59% of people with obesitysay theyre interested in trying these medications.
-
Current lawprevents Medicarefrom covering them, despite growing medical and public support.
About the study
The nationally representative poll found that83% of respondents aged 50 to 80believe insurance should cover weight management drugs. When asked specifically aboutMedicare,75% agreedit should provide coverage. That number dropped to30%when people were told it might raise their premiums.
The survey results come as federal health officials are considering anew rulethat could allow Medicare tostart covering anti-obesity drugs something it has never done before. Currently, Medicare only covers certain weight-loss drugs when prescribed for related conditions like diabetes or heart disease.
Strong interest, limited access
Despite limited coverage,interest in using these medications is high, especially among those who meet medical guidelines for obesity.
-
59% of people with a BMI of 30 or highersaid they are interested in trying weight-loss drugs.
-
That interest drops to29%among those who are overweight but not obese (BMI 2729.9).
Yet only a small share have actually used these drugs before. The most commonly used medication wasphentermine, with10%of respondents saying theyd tried it. Newer medications likeOzempicorWegovywere used by fewer than2%.
Public opinion & policy shifts
The study found that people who understandobesity as a chronic condition not just a lifestyle issue are far more likely to support insurance coverage for these medications. In fact,90% agreedthat obesity results from a mix ofgenetics, environment, and health conditions.
Lead authorDr. Lauren Oshmansaid the findings are timely, especially as the country faces the high costs of treating obesity-related diseases and the rising demand forGLP-1 drugslike semaglutide (sold as Ozempic and Wegovy).
Later this year,Medicare is expected to begin price negotiationswith drug makers a move that could shape future coverage and affordability.
The poll included2,657 adultsand was conducted insummer 2023by the U-M Institute for Healthcare Policy and Innovation andAARP.
Posted: 2025-03-26 19:08:46